Cancer Research extends its congratulations and best wishes to the National Institutes of Health (NIH) on its centennial celebration this year. The NIH is the largest and most successful enterprise in biomedical research in the world. Its past growth and achievements augur a brilliant future. Happy birthday!

The NIH is now composed of 14 separate institutes and includes the John Fogarty International Center and the National Library of Medicine. With a current budget of $6.5 billion it funds about 75% of all biomedical research in the United States. It is a fertile breeding ground for academic scientists through the world and boasts among its current and former members an impressive number of Nobel laureates, as well as many other awardees.

A history of the NIH has recently been published by the Johns Hopkins Press (Victoria A. Harden, Inventing the NIH: Federal Biomedical Research Policy, 1887–1937, 1986).

The cover shows a panoramic view of the NIH campus in Bethesda, and James Wyngaarden, the current Director.
GRANTS AVAILABLE

for
Research on the Resistance of Human Tumors to Chemotherapeutic Agents

Bristol-Myers Company is pleased to announce a $16,000,000 drug resistance research funding program. The goal of this research program is to identify the mechanisms by which human tumors become resistant to chemotherapy and to develop and test methods of overcoming such resistance. Grants will be awarded in two categories. Laboratory grants will be $100,000 per year for five years. Five year grants of $200,000 per year will be awarded for research which directly tests laboratory findings in human trials.

Applications are invited from qualified investigators worldwide. Applicants may be associated with academic institutions, research institutes, government laboratories or other facilities capable of conducting these types of investigations. Applications will not be accepted from individuals affiliated with or employed in the pharmaceutical industry or engaged in for-profit research.

Applications will be accepted until January 1, 1988 and will then be reviewed by a panel of experts, independent of Bristol-Myers. Awards will be announced on or about April 1, with funding commencing July 1, 1988. Additional information about this program can be obtained by writing:

Mr. Gary Doyle
Program Coordinator
Bristol-Myers Company
5 Research Parkway
P.O. Box 5100
Wallingford, CT 06492-7660
U.S.A.